BRAF-话题@MedSci

#BRAF#

112篇内容 | 3435人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1355014, encodeId=463c1355014a4, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果, objectType=article, longId=186510, objectId=455918651038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=455918651038, replyNumber=0, likeNumber=65, createdTime=2020-01-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=455918651038, moduleTitle=BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=455918651038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355013, encodeId=337e135501385, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可, objectType=article, longId=183896, objectId=82f1183896b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82f1183896b9, replyNumber=0, likeNumber=67, createdTime=2019-12-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82f1183896b9, moduleTitle=璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82f1183896b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355012, encodeId=f56f13550128a, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌, objectType=article, longId=181909, objectId=dfaf18190961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfaf18190961, replyNumber=0, likeNumber=133, createdTime=2019-10-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfaf18190961, moduleTitle=NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfaf18190961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355011, encodeId=d2601355011dd, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=BRAF突变肠癌治疗新进展, objectType=article, longId=178564, objectId=93a81e8564a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93a81e8564a4, replyNumber=0, likeNumber=108, createdTime=2019-09-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93a81e8564a4, moduleTitle=BRAF突变肠癌治疗新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93a81e8564a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355010, encodeId=d43113550109b, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效, objectType=article, longId=177709, objectId=11801e770906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11801e770906, replyNumber=0, likeNumber=78, createdTime=2019-08-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11801e770906, moduleTitle=NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11801e770906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355009, encodeId=45711355009e9, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Clinica Chimica Acta：用液滴数字PCR检测乳头状甲状腺癌细针穿刺液中BRAF V600E突变, objectType=article, longId=177023, objectId=72ff1e702301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72ff1e702301, replyNumber=0, likeNumber=59, createdTime=2019-08-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72ff1e702301, moduleTitle=Clinica Chimica Acta：用液滴数字PCR检测乳头状甲状腺癌细针穿刺液中BRAF V600E突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72ff1e702301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355008, encodeId=97ce135500812, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, objectType=article, longId=175233, objectId=c5631e5233ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5631e5233ba, replyNumber=0, likeNumber=98, createdTime=2019-07-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5631e5233ba, moduleTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5631e5233ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355007, encodeId=50ab135500e3f, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=David Planchard教授：BRAF突变NSCLC治疗进展, objectType=article, longId=175205, objectId=a0d21e5205ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0d21e5205ae, replyNumber=0, likeNumber=59, createdTime=2019-07-13, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0d21e5205ae, moduleTitle=David Planchard教授：BRAF突变NSCLC治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0d21e5205ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355006, encodeId=5fcd1355006ec, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=早期精准诊断：4分钟读懂黑色素瘤BRAF突变检测的重要性, objectType=article, longId=167433, objectId=128b16e43377, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=128b16e43377, replyNumber=0, likeNumber=68, createdTime=2019-06-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=128b16e43377, moduleTitle=早期精准诊断：4分钟读懂黑色素瘤BRAF突变检测的重要性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=128b16e43377)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355005, encodeId=93b61355005d7, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率, objectType=article, longId=166645, objectId=66b1166645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66b1166645d2, replyNumber=0, likeNumber=55, createdTime=2019-05-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66b1166645d2, moduleTitle=Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66b1166645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355004, encodeId=848613550044b, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, objectType=article, longId=158891, objectId=8a5b15889101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a5b15889101, replyNumber=0, likeNumber=63, createdTime=2019-01-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a5b15889101, moduleTitle=NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a5b15889101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355003, encodeId=395c13550037b, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=CLIN CANCER RES：BRAF突变种类对BRAF突变肺癌预后的影响, objectType=article, longId=158587, objectId=64b915858ebd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64b915858ebd, replyNumber=0, likeNumber=76, createdTime=2019-01-23, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64b915858ebd, moduleTitle=CLIN CANCER RES：BRAF突变种类对BRAF突变肺癌预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64b915858ebd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355002, encodeId=98a3135500252, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=【ASCO-GI 2019】抢先看！达拉非尼联合曲美替尼在BRAF V600E突变的胆管癌患者中的研究, objectType=article, longId=158427, objectId=4af815842edc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4af815842edc, replyNumber=0, likeNumber=70, createdTime=2019-01-20, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4af815842edc, moduleTitle=【ASCO-GI 2019】抢先看！达拉非尼联合曲美替尼在BRAF V600E突变的胆管癌患者中的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4af815842edc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355001, encodeId=6cb913550014c, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=CLIN CANCER RES：双重MAPK抑制治疗II类BRAF突变黑素瘤, objectType=article, longId=156471, objectId=aaca1564e1e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aaca1564e1e0, replyNumber=0, likeNumber=68, createdTime=2018-12-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aaca1564e1e0, moduleTitle=CLIN CANCER RES：双重MAPK抑制治疗II类BRAF突变黑素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aaca1564e1e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355000, encodeId=620a135500042, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=CLIN CANCER RES：BRAF和HSP90抑制剂联合治疗不可切除的黑色素瘤, objectType=article, longId=154006, objectId=cf53154006f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf53154006f7, replyNumber=0, likeNumber=68, createdTime=2018-11-22, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf53154006f7, moduleTitle=CLIN CANCER RES：BRAF和HSP90抑制剂联合治疗不可切除的黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf53154006f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354999, encodeId=68ae135499968, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益, objectType=article, longId=152422, objectId=77eb15242261, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77eb15242261, replyNumber=0, likeNumber=116, createdTime=2018-11-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77eb15242261, moduleTitle=JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77eb15242261)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354998, encodeId=937113549985c, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=JCO：BRAF抑制治疗BRAF V600突变胶质瘤, objectType=article, longId=152420, objectId=bcd3152420dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcd3152420dc, replyNumber=0, likeNumber=66, createdTime=2018-11-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcd3152420dc, moduleTitle=JCO：BRAF抑制治疗BRAF V600突变胶质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcd3152420dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354997, encodeId=898b135499e28, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=双拳出击，BRAF突变型晚期NSCLC一线治疗新选择, objectType=article, longId=152265, objectId=a82f152265d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a82f152265d3, replyNumber=0, likeNumber=109, createdTime=2018-10-31, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a82f152265d3, moduleTitle=双拳出击，BRAF突变型晚期NSCLC一线治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a82f152265d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354996, encodeId=de701354996e2, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, objectType=article, longId=149597, objectId=26f714959eaf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26f714959eaf, replyNumber=0, likeNumber=78, createdTime=2018-09-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26f714959eaf, moduleTitle=Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26f714959eaf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1354995, encodeId=a343135499566, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet oncol：Encorafenib联合binimetinib治疗BRAF突变型黑色素瘤总体存活率效益显著, objectType=article, longId=148780, objectId=15b2148e8062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15b2148e8062, replyNumber=0, likeNumber=87, createdTime=2018-09-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15b2148e8062, moduleTitle=Lancet oncol：Encorafenib联合binimetinib治疗BRAF突变型黑色素瘤总体存活率效益显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15b2148e8062)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRAF

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果

2020-01-20

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可

2019-12-02

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌

2019-10-26

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

BRAF突变肠癌治疗新进展

2019-09-03

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

NEJM：Dabrafenib加Trametinib治疗转移性黑色素瘤的五年疗效

2019-08-17

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Clinica Chimica Acta：用液滴数字PCR检测乳头状甲状腺癌细针穿刺液中BRAF V600E突变

2019-08-08

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗

2019-07-13

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

David Planchard教授：BRAF突变NSCLC治疗进展

2019-07-13

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

早期精准诊断：4分钟读懂黑色素瘤BRAF突变检测的重要性

2019-06-02

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Braftovi、Mektovi与Erbitux的联合使用可提高转移性结直肠癌患者的生存率

2019-05-24

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

NICE推荐BRAF激酶抑制剂与MEK抑制剂联合治疗BRAF V600突变的黑素瘤患者

2019-01-27

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

CLIN CANCER RES：BRAF突变种类对BRAF突变肺癌预后的影响

2019-01-23

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

【ASCO-GI 2019】抢先看！达拉非尼联合曲美替尼在BRAF V600E突变的胆管癌患者中的研究

2019-01-20

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

CLIN CANCER RES：双重MAPK抑制治疗II类BRAF突变黑素瘤

2018-12-24

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

CLIN CANCER RES：BRAF和HSP90抑制剂联合治疗不可切除的黑色素瘤

2018-11-22

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JCO：Dabrafenib联合Trametinib对BRAFV600突变Ⅲ期黑色素瘤患者无复发生存有益

2018-11-01

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

JCO：BRAF抑制治疗BRAF V600突变胶质瘤

2018-11-01

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

双拳出击，BRAF突变型晚期NSCLC一线治疗新选择

2018-10-31

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Braftovi/Mektovi联合欧洲获批用于治疗BRAFV600突变的不可切除或转移性黑色素瘤

2018-09-27

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet oncol：Encorafenib联合binimetinib治疗BRAF突变型黑色素瘤总体存活率效益显著

2018-09-15

科室
- - 订阅+
  - 更多科室
工具
服务